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Cyclic dinucleotides (CDNs) have been previously recognized as important secondary signaling
molecules in bacteria and, more recently, in mammalian cells. In the former case, they represent
secondary messengers affecting numerous responses of the prokaryotic cell, whereas in the latter,
they act as agonists of the innate immune response. Remarkable new discoveries have linked these
two patterns of utilization of CDNs as secondary messengers and have revealed unexpected influ-
ences they likely had on shaping human genetic variation. This Review summarizes these recent
insights and provides a perspective on future unanswered questions in this exciting field.Cyclic di-GMPas aSecondMessenger inGram-Negative
Bacteria
Cyclic dinucleotides (CDNs) were originally described more than
25 years ago as activators of bacterial cellulose synthase (Ross
et al., 1987). These investigators defined cyclic di-GMP (cdG) as
twoGMPmolecules linked in a heterocyclic configuration via two
30-50 phosphodiester bonds. However, only in 1998 did Tal and
colleagues suggest that cdG may be important for other pro-
cesses in bacteria (Tal et al., 1998). Since then, cdG has been
implicated in central bacterial processes, including, but not
limited to, virulence, stress survival, motility, antibiotic produc-
tion, metabolism, biofilm formation, and differentiation (reviewed
in detail in Ro¨mling et al. [2013]). In Gram-negative bacteria, cdG
is now accepted as a universal bacterial secondarymessenger in
that genes encoding enzymes involved in synthesis and degra-
dation of this CDN are recognizable in the genomes of all corre-
sponding bacterial species.
The cytosolic level of cdG in bacterial cells is tightly controlled
by the dual activity of diguanylate cyclases (DGCs) with GGDEF
domains and phosphodiesterases (PDEs) with EAL or HD-GYP
domains. The large number of enzymes that are involved in
cdG-related pathways (for example, Vibrio cholerae encodes
72 DGC and PDE proteins) suggests tremendous complexity
of cdG-mediated signaling in bacteria. Intriguingly, analyses
show that genomes carry many genes encoding multidomain
proteins that encode both DGC and PDE domains. However, in
the majority of these cases, only one domain is active while the
other one is involved in protein-protein or protein-RNA interac-
tions. Even more diverse is the number of receptors that have
been implicated in cdG sensing in ways that alter cellular activity
by modifying transcription, translation, or protein activity (Ro¨m-
ling et al., 2013). Thus far, we know that bacteria can sense their
environment and respond by modulation of cdG levels to stimuli
that include O2 and NO levels, light flux, redox state, and the
stage of the cell cycle (Mills et al., 2011). However, our knowl-
edge of the regulatory networks in which cdG (or other CDNs,
see below) are involved is far from complete, and further962 Cell 154, August 29, 2013 ª2013 Elsevier Inc.research on environmental stresses, cdG-binding effectors,
and the pathways that CDNs control is still needed. Newly devel-
oped methods such as fluorescence resonance energy transfer
(FRET)-based biosensors that allow the monitoring of cdG
concentrations within single bacterial cells (Christen et al.,
2010), differential radial capillary action of ligand assay
(DRaCALA) that allows rapid and high-throughput measuring
of protein-CDN interactions (Roelofs et al., 2011), and develop-
ment of similar tools for other CDNs will eventually lead to signif-
icant advances in the field.
Cyclic di-AMP in Gram-Positive Bacteria
In addition to the role of cdG as a central signaling molecule
in Gram-negative bacteria, recent discoveries suggest that
cyclic di-AMP (cdA) plays an important role, particularly in
many Gram-positive bacteria. The diadenylate cyclase (DAC,
DUF147) domain is found in almost 2,000 hypothetical proteins
encoded by numerous bacterial species, and many of these
DACs are fused to domains of unknown functions (Corrigan
and Gru¨ndling, 2013), suggesting that signaling pathways for
cdA are probably as complex and widespread as for cdG. The
best-characterized DAC enzymes are from Bacillus subtilis:
DisA and CdaS (YojJ) are required for sporulation, whereas
another DAC CdaA (YbbP) is involved in cell wall biosynthesis
(Mehne et al., 2013; Oppenheimer-Shaanan et al., 2011; Witte
et al., 2008). Supporting evidence for the role of cdA in cell wall
homeostasis comes from a study by Luo and Helmann (2012)
that showed that overproduction of cdA phosphodiesterase
gdpP (yybT) sensitizes B. subtilis to ampicillin, similar to a strain
in which the gene encoding a cdA synthetase is deleted. A com-
parable antibiotic susceptibility phenotype was observed in
Staphylococcus aureus and Listeria monocytogenes (Corrigan
et al., 2011; Witte et al., 2012). In Mycobacterium smegmatis,
overexpression of a DisA homolog was linked to changes in
cell morphology and motility (Zhang and He, 2013).
Although the functions of cdA are far from being understood,
observations that deletion of cdA synthetase are lethal in
L. monocytogenes, Streptococcus pneumonia, S. aureus, and
B. subtilis suggest that cdA controls central cellular pathways
in many Gram-positive organisms. Corrigan and colleagues
suggested that essentiality of the cdA oligonucleotide might be
due to a cumulative effect on cdA receptors (Corrigan et al.,
2013). Their recent work identified a potassium transporter,
KtrA, a cation/proton antiporter, CpaA, a PII-like signal transduc-
tion protein A, PstA, and a sensor histidine kinase, KdpD, as
specific receptors for cdA in S. aureus (Corrigan et al., 2013). It
is possible that simultaneous inactivation of these and possibly
other unidentified proteins under cdA control can, in sum, have
a lethal effect on a cell that is experiencing depletion of cdA.
Cyclic AMP-GMP in V. cholerae
A new type of CDN called cyclic AMP-GMP (cAMP-GMP) was
recently identified by Mekalanos and colleagues as a signaling
molecule in Vibrio cholerae that is involved in virulence (Davies
et al., 2012). This hybrid molecule is synthesized by the enzyme
dinucleotide cyclase or DncV, a protein that shows similarity to
eukaryotic 20-50 oligo-adenylate synthetase (OAS1). However,
evidence suggests that DncV produces a CDN composed of
AMP and GMP linked by two 30-50 phosphodiester bonds
(Ablasser et al., 2013; Davies et al., 2012; Diner et al., 2013). Pre-
dicted orthologs of DncV are also recognizable in many other
Gram-negative and -positive bacterial species (Davies et al.,
2012). Interestingly, in addition to its function as synthase for
cAMP-GMP, DncV can also synthesize cdA and cdG, thus
raising a possibility that one enzyme can control the pool size
of multiple CDNs in the bacterial cell. Thus, some CDN-binding
effectors (and CDN degradation enzymes) might have specific
or overlapping specificities toward cdA, cdG, and cAMP-
GMP. Overexpression of DncV inhibits the chemotactic
response of V. cholerae, a phenotype that has been linked to hy-
perinfectivity by Camilli and colleagues (Butler et al., 2006).
Because chemotaxis is not altered by overexpression of a
cdG synthetase in V. cholerae, these data suggest that different
CDNs could alter different regulatory networks within the same
cell. These networks are likely to be more complex in the light of
the possibility that there might be spatially and temporally
distinct pools of CDNs controlling any given phenotype (Linden-
berg et al., 2013).
Recognition of Pathogens by Host Innate Immune
Receptors
Microbial organisms express molecules that can be chemically
differentiated from those produced by host cells and, thus, can
be targeted for recognition by receptors of the innate immune
system. The term pathogen-associated molecular patterns
(PAMPs) has been coined to define such microbial signaling
agonists, and the receptors that recognize these agonists are
referred to as pattern recognition receptors (PRRs) (Iwasaki
and Medzhitov, 2010). Innate immune agonists include lipid A
derived from lipopolysaccharides, peptides encodedwithin bac-
terial flagellin, peptidoglycan fragments, lipopeptides, microbial
polysaccharides, and certain types of nucleic acids, among
others molecules (Takeuchi and Akira, 2010). In some cases,
hostmolecules can be recognized as ‘‘PAMP like’’ if they are pre-
sent in an abnormal subcellular context (e.g., the presence ofDNA in the cytosol rather than in the nucleus) (Barber, 2011a;
Vance et al., 2009). This strategy for innate immune recognition
can be rationalized by the host’s need to detect the genetic prod-
ucts of pathogen replication within the cytosol, as well as the
cellular disruptions caused by intracellular pathogens. Accord-
ingly, host cells express a spectrum of PRRs in plasma mem-
brane, vacuolar membranes, and cytosol in order to detect
threats that have different anatomical and subcellular locations
during pathogenesis (Palm and Medzhitov, 2009). The recogni-
tion of PAMPs by PRRs activates host cell signal transduction
cascades that drive production of interferons (IFNs) and other
proinflammatory cytokines, as well as antipathogen effector
molecules, thereby triggering protective cell biological changes
(e.g., inflammasome activation, apoptosis, and autophagy)
needed to limit pathogen growth within infected cells (Baxt
et al., 2013). The innate immune response also stimulates
many elements of the adaptive immune system in order to mar-
shal a specific counterattack on the detected microbial threat.
Thus, PAMPs have been recognized for some time as potent
adjuvants in the context of vaccines and immunotherapeutics
(Duthie et al., 2011). The presence of CDNs in virtually all known
bacteria and the fact that eukaryotes were not previously known
to rely on these secondary messenger molecules suggested that
CDNsmight be PAMPs. Early evidence for this concept was pro-
vided by the observation that cdA and cdG had adjuvant and
immunomodulatory activity in mice (Ebensen et al., 2011; Kara-
olis et al., 2007) and that STING was the innate immune receptor
of bacterial CDNs (see below) (Burdette et al., 2011).
PRR Activation by Innate Immune Agonists
Several different types of PRRs are now recognized. In brief, Toll-
like receptors (TLRs) play major roles in the recognition of
PAMPs within the extracellular milieu and endosomal lumen
(Kawai and Akira, 2011). TLR activation occurs after ligand
(agonist) binding and leads to the recruitment of the adaptormol-
ecules MyD88 and TRIF and subsequent activation of a kinase-
driven signaling pathway, culminating in activation of NF-kB and
IRF3/7 and thereby host gene expression (Dev et al., 2011).
Nucleotide-binding domain leucine-rich repeat-containing pro-
teins (NLRs) are PRRs that reside in the cytosol and most often
are activated by bacterial products such as peptidoglycan frag-
ments and peptides derived from flagellin, the type III secretion
system rod components, toxins, bacterial, and viral double-
stranded DNA (dsDNA) (Franchi et al., 2012). Besides NLRs,
additional cytosolic innate receptors exist, including RNA heli-
cases of the retinoic acid-inducible gene-1 (RIG-1)-like receptors
(RLRs), which typically recognize cytosolic viral dsRNA and then
recruit the adaptor IFN-b promoter stimulator 1 (IPS-1; also
called MAVS, VISA, and Cardif), leading to phosphorylation of
the transcription factors IRF-3 and IRF7 and expression of
Type I IFN genes (Loo and Gale, 2011). Another non-NLR is ab-
sent in melanoma 2 (AIM2), an interferon-inducible protein that
can bind dsDNA in the cytosol and induce autocleavage of cas-
pase-1 and thereby inflammasome activation (Barber, 2011b).
C-type lectin receptors (CLRs) such as Dectin-1 bind fungal
cell wall components and trigger activation of NF-kB (Takeuchi
and Akira, 2010). Given that PRRs can detect PAMPs associated
with all pathogenic microorganisms, it seems likely that evenCell 154, August 29, 2013 ª2013 Elsevier Inc. 963
Table 1. Examples of Bacterial and Viral Proinflammatory Response Modifications
Organism Effector protein Mechanism Target Reference
Bacillus anthracis lethal factor metalloprotease MAPK kinase (Duesbery et al., 1998)
Chlamydia trachomatis ChlaDub1, 2 DUB, deneddylase IkBa (Le Negrate et al., 2008b)
CT441 protease RelA (Lad et al., 2007)
Pathogenic E. coli;
B. pseudomallei
Cif; CHBP deaminase ubiquitin and ubiquitin-like
protein NEDD8
(Cui et al., 2010; Jubelin et al., 2010)
Pathogenic E. coli NleC protease RelA (Yen et al., 2010)
Yersinia spp. YopJ acetyltransferase RICK, TAK1 (Meinzer et al., 2012)
YopM inhibitor caspase-1 (LaRock and Cookson, 2012)
Legionella pneumophila LegK1 Ser/Thr-kinase IkBa, p100 (Ge et al., 2009)
Salmonella Typhimurium AvrA acetyltransferase IKKa/b (Jones et al., 2008)
SseL DUB IkBa (Le Negrate et al., 2008a)
SspH1 E3 ligase PKN1 (Ashida et al., 2010; Haraga and Miller, 2006)
Shigella spp. IpaH9.8 E3 ligase NEMO (Ashida et al., 2010)
OspF phosphothreonine lyase MAPK kinases (Li et al., 2007)
OspG Ser/Thr-kinase UbcH5 (E2) (Kim et al., 2005)
HSV-1 ICP27 IkBa (Kim et al., 2008)
ICP0 E3 ubiquitin ligase IFI16 (Orzalli et al., 2012)
Influenza A NS1 TRIM25 and Riplet (Rajsbaum et al., 2012)
Vaccinia virus B14R IKKb (Chen et al., 2008)
CP77 SCF complex, p65 (Chang et al., 2009)
N1L TBK1 (DiPerna et al., 2004)
K1L IKK (Shisler and Jin, 2004)prions might be detected by some element of the innate immune
system because of the unusual b-amyloid structures they can
form and the cellular disruptions that these polymers cause
(Bradford and Mabbott, 2012; Sheedy et al., 2013).
Despite the presence of multiple PRRs in various cell compart-
ments, both bacteria and viruses have developed mechanisms
that allow them to avoid intracellular killing and subvert induction
of the innate immunity. These include downregulation or modifi-
cation of innate immune agonists such as flagellin (Gru¨ndling
et al., 2004) or lipid A (Trent et al., 2006). In the case of bacteria,
effectors delivered by type III and IV systems have also been
shown to modify many different cellular pathways, including
those involved in innate immune responses (Baxt et al., 2013;
Gala´n, 2009). In some cases, bacterial effectors are similar in
function to eukaryotic proteins that are involved in central cellular
processes such as phosphorylation, ubiquitination, and Rho
family GTPase signaling. In other cases, bacterial effectors are
capable of targeting host proteins by modifying their function
by dephosphorylation, acetylation, AMPylation, and N-myristoy-
lation (Hicks and Gala´n, 2013). Among themyriad effects on host
cells, bacterial effectors trigger blocks in signal transduction,
avoidance of autophagy, interference with proinflammatory
responses, and modifications of vesicular trafficking (Baxt
et al., 2013) (Table 1). Similarly, viruses can suppress host IFN
induction by various mechanisms, including, for example, inhibi-
tion of RIG-I signaling by blocking its ubiquitination by the
TRIM25 ubiquitin E3 ligase (Rajsbaum et al., 2012) (Table 1).
Thus, innate immune signaling is clearly a host response that
pathogenic microorganisms have learned to manipulate through964 Cell 154, August 29, 2013 ª2013 Elsevier Inc.effector protein action as well as alterations in the production of
innate immune agonists, including CDNs (see below).
Activation of the Type I Interferon Response by STING
Among the downstream effectors of the signaling cascade
driven by activation of PRRs are specific cytokines and chemo-
kines, including the type I interferons (IFN-a/b). These secreted
cytokines can be produced in response to either viral or bacterial
intracellular infections through signaling pathways that have only
recently been revealed in molecular detail. For example, cyto-
solic DNA induces a type I IFN response that is dependent on
a protein called STING (also known as ERIS, MITA, MPYS, and
TMEM173), an endoplasmic reticulum (ER)-localized transmem-
brane protein (Ishikawa and Barber, 2008). The STING-depen-
dent, type I IFN response appears to be critical to limit the
replication of DNA viruses such as HSV-1 (Ishikawa and Barber,
2008). Although there is evidence that STINGmay directly recog-
nize dsDNA with low affinity (Kd > 200 mM) (Abe et al., 2013), this
is unlikely to be a critical property of STING in light of new infor-
mation (see below). However, the pathway to type I IFN produc-
tion after STING activation seems quite clear (Burdette et al.,
2011). After a DNA recognition signal is received within the
cytosol, STING is ‘‘activated,’’ and this corresponds with its relo-
cation to discrete foci in the cell cytoplasm. These cell biological
changes correlate with recruitment of the kinases TBK1 and IKK,
which in turn activate IRF3, STAT6, and NF-kB, resulting in type I
IFN induction (Cavlar et al., 2012) (Figure 1). The biochemical
connection between cytosolic DNA recognition and activation
of STING has been elegantly revealed by the recent work of
Figure 1. Overview of STING-Dependent Interferon Induction
Infection of eukaryotic cells with viruses, protozoa, and bacteria leads to
accumulation of extracellular DNA that signals the presence of pathogens to
the cellular immune system. Cytosolic dsDNA is recognized by cGAS in a
sequence-independent manner. cGAS induces production of 20-50, 30-
50cGAMP to stimulate STING. At least some STING alleles (such as R232) can
additionally be activated by CDNs produced by bacteria that include cdA,
cdG, and 30-50, 30-50cGAMP (cAMP-GMP), whereas other STING alleles (such
as H232) are not responsive to bacterial CDNs. Binding of STING to an acti-
vating ligand induces conformational change in STING, resulting in formation
of a ‘‘closed form’’ in which ligand is tightly bound to the binding pocket.
Following relocation of STING to discrete foci in the cell cytosol, activated
STING recruits TBK1 and IKK kinases, which in turn activate IRF-3, STAT6, and
NF-kB. Upon translocation of activated transcriptional factors to the nucleus,
they bind to corresponding promoters, thus resulting in induction of type I IFN
and cytokines.Chen and colleagues (Sun et al., 2013; Wu et al., 2013) (see
below).
The generation of STING mutant mice (Goldenticket or Gt
mice) has greatly facilitated the identification of other STING-
dependent pathways for induction of type I IFNs, implicating
this molecule in the sensing of PAMPs produced by intracellular
bacterial pathogens (Jin et al., 2011a; Sauer et al., 2011). STING
was eventually shown to directly bind to cdG, and STING
mutants defective in such binding lose their ability to induce
the production of type I IFNs in response to bacterial CDNs
(Burdette et al., 2011). Consistent with this discovery, there
are now several lines of evidence suggesting that bacterial
CDNs can gain access to the host cell cytosol during
infection. For example, the cytosolic intracellular pathogen
L. monocytogenes utilizes an efflux pump to secrete cdA directly
into the host cytosol, where it triggers a STING-dependent pro-
duction of type I IFNs in mouse cells (Woodward et al., 2010).
Mutants of L. monocytogenes that are confined to the vacuolar
lumen do not induce production of IFN-b, suggesting that thispathogen must escape the endosome to deliver cdA to the
cytosol. More recently, it was shown that concentration of cdA
in cytosol of Chlamydia-infected mouse macrophages is greatly
increased compared to uninfected cells and that this correlated
with STING-dependent activation of the type I IFN response
(Barker et al., 2013). Thus, evidence is accumulating that cyto-
solic bacterial pathogens can modulate innate immune re-
sponses through the CDNs they produce. However, given that
some human STING alleles do not respond to bacterial CDNs
(see below), more detailed studies are needed to fully under-
stand the bacterial CDN, STING-dependent IFN response.
Synthesis of cGAMP by the Mammalian DNA Sensor
cGAS Provides the Missing Link between DNA Sensing
and STING Activation
The role of STING as the common downstream regulator of the
type I IFN response induced by both cytoplasmic DNA and
CDNs has been recently explained through the discovery by
Chen and colleagues of the enzyme cyclic GMP-AMP synthase
or cGAS (also known as C6orf150 and MB21D1) and its ability to
synthesize a CDN ligand that activated STING (Sun et al., 2013;
Wu et al., 2013). In brief, Chen and colleagues showed that, in
the presence of dsDNA, cGAS selectively catalyzed the synthesis
of cAMP-GMP (which they termed cGAMP) and that, after STING
binds this endogenous CDN, it activates the type I IFN response
(Sun et al., 2013; Wu et al., 2013). Like most major advances, the
discovery of cGAS gave rise to a new series of questions. How is
cGASactivated by recognition of only dsDNA in a sequence-inde-
pendent fashion? Given that cGAS belongs to the same nucleoti-
dyltransferase (NTase) family as DncV, is it making exactly the
same hybrid CDN as the bacterial enzyme? If so, how could this
conclusion be reconciled with the existence of a mutant STING
allele (H231) that was not responsive to cdG and cdA but still
able to sense dsDNA? Do all naturally occurring STING alleles
recognize all CDNswith equal affinity? Recently, a series of seven
papers have been published that answermany of these questions
(Ablasser et al., 2013; Civril et al., 2013; Diner et al., 2013; Gao
et al., 2013a, 2013b; Kranzusch et al., 2013; Zhang et al., 2013).
Crystal structures of the nucleotidyl transferase (NT) domain of
porcine cGAS (residues 135–497) (Civril et al., 2013), mouse
cGAS (147–507) (Gao et al., 2013a), and human cGAS (residues
157–522) (Kranzusch et al., 2013) have been solved with or
without dsDNA ligand and nucleotide substrates. cGAS is a
60 kDa protein that consists of protease-sensitive, unstructured,
and poorly conserved150 amino-acid-long N-terminal domain
and a protease-resistant, conserved NTase C-terminal domain.
cGAS dinucleotide synthase activity is dependent on the pres-
ence of dsDNA, Mg2+ or Mn2+, ATP, and GTP. The crystal struc-
tures revealed that the catalytic NTase domain fold shows high
similarity to an RNA sensor 20-50 oligo-adenylate synthetase 1
(OAS1) (Donovan et al., 2013). cGAS interacts with the sugar-
phosphate backbone along theminor groove of DNA, thus deter-
mining its specificity toward dsDNA in a sequence-independent
manner. In comparison to other NTase-containing enzymes,
vertebrate cGAS contains a zinc-ribbon domain with an atypical
H(X5)CC(X6)C motif that is essential for a metal coordination and
interaction with themajor groove of DNA, suggesting that it func-
tions as a molecular ‘‘ruler’’ that determines specificity of cGASCell 154, August 29, 2013 ª2013 Elsevier Inc. 965
toward dsDNA (Civril et al., 2013; Kranzusch et al., 2013). Bind-
ing of DNA to cGAS induces structural changes that result in re-
arrangement of catalytic residues in the NTase active site and
enzyme activation. Given the similarity in the NTase fold of
OAS1 and cGAS and the fact that both enzymes make second-
ary messenger molecules in response to detected nucleic acids,
it seems likely that cGAS and OAS constitute a novel evolu-
tionary conserved group of PRRs, the OAS-like second
messenger receptors (OLRs), that evolved to detect the nucleic
acids of cytosolic pathogens (Kranzusch et al., 2013).
Discovery of the Second ‘‘Missing Link’’ Corresponding
to a Unique Bond in Mammalian cGAMP
Further characterization of cGAS showed that the enzyme pro-
duces a CDN that has a very rare in nature 20-50 phosphodiester
linkage betweenGMP and AMP followed by a 30-50 return linkage
from AMP to GMP (Ablasser et al., 2013; Diner et al., 2013; Gao
et al., 2013a; Kranzusch et al., 2013; Zhang et al., 2013). This
CDN isomer (designated here 20-50, 3-50cGAMP for simplicity)
is different from all characterized bacterial CDNs, including
cAMP-GMP synthesized by DcnV, which is apparently a 30-50,
30-50 isomer (Ablasser et al., 2013; Davies et al., 2012; Diner
et al., 2013). Thus, the phosphodiester linkages of the cGAS
product are different in structure than the initially proposed
30-50, 30-50cGAMP isomer (Wu et al., 2013). The cGAS product
has been confirmed to be the 20-50, 30-50cGAMP isomer by
reverse-phase high-performance liquid chromatography
(HPLC) analysis (Ablasser et al., 2013; Gao et al., 2013a; Zhang
et al., 2013), high-resolution tandem mass spectrometry (MS/
MS) spectra of cGAS product (Ablasser et al., 2013; Zhang
et al., 2013), and nuclease digestions (Ablasser et al., 2013; Diner
et al., 2013) using a chemically synthesized cGAMP isomers as a
gold standard. NMR analysis (Ablasser et al., 2013; Diner et al.,
2013; Gao et al., 2013a; Zhang et al., 2013) and CD spectrum
(Zhang et al., 2013) also indicated that the cGAS product had
20-50 as well as 30-50 phosphodiester bonds. Furthermore,
crystallization of cGAS in the presence of ATP and GMP
clearly showed that a linear oligonucleotide corresponding to
pppG(20-50)pA was bound to its catalytic pocket, suggesting
that ring closure occurs by formation of a phosphodiester bond
between the 50 phosphate of G and the 30 OH of A (Gao et al.,
2013a). Thus, combined evidence from several groups has
confirmed that cGAS produces the 20-50, 30-50cGAMP isomer.
It remains a mystery why cGAS has evolved to make the 20-50,
30-50cGAMP. It is possible that the 20-50 phosphodiester linkage
promotes a greater stability to cGAMP product, thus allowing
stronger and more prolonged signal amplification (Gao et al.,
2013a). Furthermore, production of 20-50, 30-50cGAMP instead
of 30-50, 30-50cGAMP might be a defense mechanism of eukary-
otic cells that allows them to avoid subversion of innate immune
response by bacteria because bacterial cells might not be able
to degrade 20-50 phosphodiester linkages. While cGAMP phos-
phodiesterases are currently unknown both in bacteria and eu-
karyotes, determining how 20-50, 30-50cGAMP turnover occurs in
eukaryotic cells is a particularly exciting challenge in the field. It
would be interesting if suchenzymes (both in prokaryotesandeu-
karyotes) have substrate specificity that could differentiate 30-50,
30-50 from 20-50, 30-50 linkages and if they are strictly specific to-966 Cell 154, August 29, 2013 ª2013 Elsevier Inc.ward cGAMP molecules or also recognize other CDNs such
as cdG and cdA. Such mammalian phosphodiesterases would
be potentially interesting targets for altering CDN homeostasis
in the context of immunity and inflammation. However, as dis-
cussed below, variation in the responsiveness of naturally occur-
ringallelesof STING tobacterialCDNs,whichhaveexclusively30-
50 phosphodiester bonds, may provide clues to the evolutionary
selection that drove cGAS to make a distinctly different CDN.
The Product Specificity of the cGAS Enzyme and the
Response Selectivity of STING Variants and Mutants
Several groups have now confirmed that 20-50, 30-50cGAMP is a
strong inducer of the type I IFN response in a STING-dependent
manner (Ablasser et al., 2013; Diner et al., 2013; Gao et al.,
2013b; Zhang et al., 2013). Isothermal titration calorimetry (ITC)
experiments showed that 20-50, 30-50cGAMP binds to human
STING (hSTING), and this reaction is endothermic compared to
the 30-50, 30-50cdG binding reaction that is exothermic; these
results suggest that STING undergoes structural rearrange-
ments exclusively upon binding to 20-50, 30-50cGAMP (Zhang
et al., 2013). However, the controversy over STING preference
toward 20-50, 30-50cGAMP or bacterial 30-50, 30-50cGAMP still
remains. For example, (Zhang et al., 2013) concluded that
hSTING (carrying the more common R232 allele) has much
higher affinity for 20-50, 30-50cGAMP than 30-50, 30-50CDNs based
on titrating different CDNs into the hSTING-30-50, 30-50cdG
complex. In their hands, the affinity of 20-50, 30-50cGAMP for
STING was almost 300-fold higher than the affinity seen with
30-50, 30-50cdG and 30-50, 30-50cGAMP. In contrast, Patel and
his group did ITC experiments and directly measured binding
of mSTING R231 and A231 alleles and hSTING H232 and R232
alleles (position 231 in mSTING is identical to 232 in hSTING)
to cGAMP isomers (Gao et al., 2013a). They were able to show
that all alleles of STING bind to 20-50, 30-50 and 30-50, 30-50cGAMP
with similar affinity and observed only a 2-fold difference
between 20-50, 30-50cGAMP and 30-50, 30-50cGAMP in STING acti-
vation. Although 20-50, 30-50cGAMP was 10- to 20-fold more
potent at inducing an interferon response in cells than 30-50,
30-50cdG, this variation could reflect different efficiencies of
cellular uptake of these two different CDNs because digitonin
was used to permeabilize cells. These binding experiments
correlate well with the in vitro data of Zhang and colleagues
showing that both 20-50, 30-50cGAMP and 30-50, 30-50cGAMP
can induce a strong IFN signaling response in the mouse cell
line L929 carrying the R231 allele (Zhang et al., 2013), similar
to what is seen with the hSTING R232 allele (Diner et al., 2013).
Curiously, neither Diner et al. (2013) nor Ablasser et al. (2013)
observed activation of the hSTINGH232 allele by the DncV prod-
uct (presumably 30-50, 30-50cGAMP), although this hSTING allele
does respond to the 20-50, 30-50cGAMP cGAS product. The
different experimental approaches and STING alleles used by
various investigators make it difficult to draw consensus con-
clusions regarding a correlation between binding affinity and
signaling strength for different CDNs and their isomers. In
contrast, new STING structural studies have advanced our
understanding in this area quite dramatically.
Crystal structures of both mouse STING (mSTING) and
hSTING R232 (residues 139–379) revealed that 20-50, 30-50 and
Figure 2. Model of STING Binding to CDNs
In its ‘‘open’’ form, STING does not fully encapsulate cdG and possibly other
bacterial 30-50, 30-50CDNs. STING structure is more flexible; partially
disoriented loops are covering the binding pocket. Binding of 20-50,
30-50cGAMP to STING happens at a deeper pocket compared to cdG and
results in formation of the ‘‘closed’’ form. STING it its closed form is more
compact, and the binding pocket is covered by a four-stranded b sheet cap.
RCSB Protein Data Bank coordinates: cdG-hSTING H232 complex (4EF4) and
20-50, 30-50cGAMP-hSTING H232 complex (4LOH).30-50, 30-50cGAMP induce a ‘‘closed’’ conformation, whereas
30-50, 30-50cdG is bound in a more ‘‘open’’ STING conformation
(Figure 2) (Gao et al., 2013b; Zhang et al., 2013). In the ‘‘closed’’
conformation, the binding pocket for cGAMP is slightly deeper
and allows coordination of 20-50, 30-50 and 30-50, 30-50cGAMP iso-
mers via extensive hydrophobic and polar interactions with
STING residues. Furthermore, crystal structures of mSTING
R231 and hSTING H232 bound to 20-50, 30-50cGAMP were found
to be identical, thus confirming that both of these STING alleles
bind this CDN in a ‘‘closed’’ conformation. In contrast, cdG only
induced the ‘‘open’’ conformation in hSTING H232, perhaps ex-
plaining why this CDN fails to significantly activate this human
STING variant (Ablasser et al., 2013; Burdette et al., 2011; Diner
et al., 2013; Gao et al., 2013b). Thus, both mSTING and R232
and H232 alleles of hSTING are responsive to 20-50, 30-50cGAMP,
but only mSTING and the R232 allele of hSTING respond to 30-50,
30-50cdG and 30-50, 30-50cGAMP (Burdette et al., 2011; Zhang
et al., 2013). Although the closed conformation was observed
earlier for hSTING solved with cdG (Huang et al., 2012), this
may be a rare conformation for the 30-50, 30-50 CDN complex
that depends more on crystallization conditions. The hSTING
H232 allele binds 20-50, 30-50cGAMP with slightly lower affinity
than the hSTING R232 allele, but the signaling response selec-
tivity for the 20-50 bond by hSTING H232 defines a clear differ-
ence between it and hSTING R232 (Diner et al., 2013; Gao
et al., 2013b). Furthermore, because mSTING (R231) binds
30-50, 30-50CDNs in a nearly identical closed conformation (Gao
et al., 2013b), the responsiveness of these two STING alleles
to the bacterial CDNs connects the closed conformation (ratherthan binding affinity per se) with downstream signaling that
induces the type I IFN response. Crystal structures of hSTING
H232 allele with 30-50, 30-50 CDNs (which do not fully activate
this protein) should provide a definitive answer to this hypothe-
sis. Together, these data suggest a view of how various alleles
of STING might function in innate immune recognition, depend-
ing on the source of the CDN signal (Figure 1). It is also worth
noting that different alleles of STING might also be activated in
some cells by binding to the DExD/H-box helicase DDX41, which
has been implicated in binding of DNA and triggering a type I IFN
response (Parvatiyar et al., 2012; Zhang et al., 2011), but the role
of cGAS and 20-50, 30-50cGAMP in this alternative pathway for
STING activation has not yet been carefully addressed. Further-
more, a recent extensive biochemical analysis has detected
numerous proteins that may contribute to the innate immune
response against cytosolic or foreign nuclear DNA (Lee et al.,
2013), but these host proteins have not been evaluated for the
role of cGAS, CDNs, or STING in their observed biochemical
interactions. Thus, there is still much to learn about how cGAS
and STING integrate their activity with multiple host responses
to foreign or mislocalized DNA.
Impact of Allele Variations in STING on Human Fitness
Variations in the hSTING locus have been documented by Jin
et al. (2011b). Approximately 18% of humans in two large
cohorts, totaling over 1,000 individuals, were found to be hetero-
zygous for the H232 allele, with the more prevalent allele being
R232 (thus, it should be considered a wild-type allele). Given
that the H232 allele is nonresponsive to 30-50, 30-50CDNs, it will
be interesting to know whether this allele is dominant (that is,
whether heterodimers with the R232 allele produce STING that
is nonresponsive to cdG). Given that certain alleles of human
STING (e.g., H232) have likely lost the specific ability to respond
to bacterial CDNs while retaining their ability to respond to the
human endogenous messenger 20-50, 30-50cGAMP produced
by cGAS, it is tempting to speculate that there was a strong se-
lective pressure to lose responsiveness to bacterial CDNs during
human evolution (Diner et al., 2013). The need to preserve a
robust innate immune response to various viruses, including
the smallpox virus and retroviruses, provides a reasonable
explanation for retaining STING responsiveness to the endoge-
nous 20-50, 30-50cGAMP produced by cGAS (Gao et al., 2013c).
However, understanding the selective pressure to ‘‘blind’’
some hSTING alleles to bacterial CDNs is more challenging
(Monroe et al., 2009). The frequency and penetrance for immune
dysfunction of such hSTING alleles in the global human popula-
tion and their geographic distribution may provide clues to the
nature of the selective process. One can envision at least two
types of selective pressure that may have been driving this hu-
man STING genetic variation: (1) bacterial CDN-driven suscepti-
bility or enhanced pathology associated with bacterial diseases
of high prevalence in certain human populations and (2) bacterial
CDN-driven alterations of nutritional or metabolic states that
significantly affected human mortality.
Selective pressure under hypothesis 1 would include expo-
sure to bacterial pathogens whose replication (and thus
virulence) was enhanced by a type I IFN response. This could
occur by the known ability of type I IFNs to polarize the adaptiveCell 154, August 29, 2013 ª2013 Elsevier Inc. 967
immune response as well as cause increased pathology by
driving excessive levels of inflammation. Bacterial invasive
diseases with high-inflammatory symptoms such as tubercu-
losis, bubonic plague, shigellosis, meningitis, enteric fever, and
pneumonias might be considered as selective drivers under
hypothesis 1 if their causative agents expose host cells to bacte-
rial CDNs during infections.Mycobacterium tuberculosis specif-
ically induces a type I IFN response by releasing bacterial DNA
into the host cell cytosol after permeabilization of a phagosomal
membrane via the activity of its virulence-associated ESX secre-
tion system (Manzanillo et al., 2012). The bacterial CDNs pro-
duced by M. tuberculosis apparently do not contribute to this
response (Manzanillo et al., 2012), and thus this pathogen may
have evolved this new way to activate STING by stimulating
production of the endogenous cGAS synthesized 20-50, 30-
50cGAMP.Mice defective in type I IFN signaling are considerably
more resistant to M. tuberculosis (Manzanillo et al., 2012), and
induction of type I IFNs exacerbates pulmonary tuberculosis in
an IFN-a/b receptor-dependent fashion (Antonelli et al., 2010).
Thus, one could easily imagine that the human host would be
under selective pressure to lower its steady-state level of STING
activation in order to counteract this pathogen’s immune modu-
lation strategy. As noted earlier, other pathogens such as
L. monocytogenes actively secrete CDNs into the cytosol of
cultured cells and directly activate the type I IFN response by a
STING-dependent pathway (Woodward et al., 2010). However,
the level of STING activation in different host tissues is largely un-
known both before and after bacterial infections. Understanding
whether susceptibility to replication or host injury by bacterial
pathogens can be altered in mice by replacement of mSTING
with the hSTING H232 allele could reveal how some bacteria
may have utilized the host response to bacterial CDNs to
enhance their own replication or fitness within the human host.
Selective pressure under hypothesis 2 might include any
STING-driven process that interferes with nutrition and thus
increases infant or child mortality through secondary effects
that could include susceptibility to severe diarrheal disease. In
this regard, recent data suggest that mutations in innate immune
pathways are enriched in patients that appear more susceptible
to cholera (Karlsson et al., 2013). Inflammatory states in the gut
are known to decrease nutrient uptake; however, little is known
about the role of STING in contributing to mucosal inflammatory
states. The large quantity of bacterial mass typically contained
within the human intestine might be a source of bacterial CDNs
that somehow find their way into host cells and produce signifi-
cant STING activation within the local intestinal epithelium.
Because the gut microbiome is also thought to play a role in
metabolic syndromes such as obesity and diabetes (Gross,
2013), it is possible that alterations in the response CDNs and
other PAMPs derived from commensal bacterial cells could be
the selected outcome of human evolution that was seeking nutri-
tional fitness in the face of famine. The fact that mutations in
receptors associated with the innate immune system have
been linked to colitis and other inflammatory conditions (Cario,
2010) underlines how little we know about the selective forces
that drove mutational changes in humans that were challenged
with pathogens as well as the need for immune homeostasis
when stimulated by a complex intestinal milieu.968 Cell 154, August 29, 2013 ª2013 Elsevier Inc.In conclusion, the newly recognized cGAS-STING-type I IFN
pathway for innate immune responses to cytosolic DNAwill likely
lead to exciting new investigations on the role of bacterial CDNs
in altering host susceptibility to pathogens as well as inflamma-
tory conditions linked to the human microbiota or disease states
that lead to leakage of nuclear DNA into the host cell cytosol.
Targeting both cGAS and STING with either activating or inhibi-
tory drugs may be a promising new strategy for treatment of
chronic infection, inflammatory states, and other diseases in
which immunomodulation of the type I IFN pathway might
show therapeutic benefit.
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